Abstract
Type 1 diabetes mellitus (T1DM) is an autoimmune disease which leads to the destruction of pancreatic β-cells, thereby causing insufficient insulin production. Globally, around 98, 200 children and adolescents below 15 years of age and almost 128,900 subjects below 20 years of age develop T1DM annually, along with severe complications deteriorating their quality of life. In India alone, around 15,900 incident cases below 15 years have reported annually. Hence, its prevention and reversal are significant. Unlike other chronic diseases, T1DM involves the presence of various autoantigens, which can be targeted by proper immunisation. The development of reliable immuno-regulatory surrogate markers would be of great benefit. Vaccines can be one of such strategies in the journey to prevent T1DM. It would not only benefit greatly to reduce the sufferings caused due to diabetic complications but could also help to reverse T1DM, by modulating the autoantigenic immunological reactions and prevent further degradation of pancreatic β-cells. This review collates a wide range of information related to the vaccine studies conducted in animal and human models to prevent and reverse T1DM.
Keywords: Type 1 diabetes mellitus, vaccine, immunomodulation, antigen vaccine, BCG vaccine, microorganisms.
Current Diabetes Reviews
Title:Vaccines For Type 1 Diabetes: Prevention or Reversal?
Volume: 17 Issue: 1
Author(s): Shivani Desai*, Shubhangi Buchade, Sohan Chitlange, Hitt Sharma, Dhiraj Bhombe, Sunil Shewale and Pramod Pujari
Affiliation:
- Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune,India
Keywords: Type 1 diabetes mellitus, vaccine, immunomodulation, antigen vaccine, BCG vaccine, microorganisms.
Abstract: Type 1 diabetes mellitus (T1DM) is an autoimmune disease which leads to the destruction of pancreatic β-cells, thereby causing insufficient insulin production. Globally, around 98, 200 children and adolescents below 15 years of age and almost 128,900 subjects below 20 years of age develop T1DM annually, along with severe complications deteriorating their quality of life. In India alone, around 15,900 incident cases below 15 years have reported annually. Hence, its prevention and reversal are significant. Unlike other chronic diseases, T1DM involves the presence of various autoantigens, which can be targeted by proper immunisation. The development of reliable immuno-regulatory surrogate markers would be of great benefit. Vaccines can be one of such strategies in the journey to prevent T1DM. It would not only benefit greatly to reduce the sufferings caused due to diabetic complications but could also help to reverse T1DM, by modulating the autoantigenic immunological reactions and prevent further degradation of pancreatic β-cells. This review collates a wide range of information related to the vaccine studies conducted in animal and human models to prevent and reverse T1DM.
Export Options
About this article
Cite this article as:
Desai Shivani *, Buchade Shubhangi , Chitlange Sohan , Sharma Hitt , Bhombe Dhiraj , Shewale Sunil and Pujari Pramod , Vaccines For Type 1 Diabetes: Prevention or Reversal?, Current Diabetes Reviews 2021; 17 (1) . https://dx.doi.org/10.2174/1573399816666200330145501
DOI https://dx.doi.org/10.2174/1573399816666200330145501 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Does Ceruloplasmin Defend Against Neurodegenerative Diseases?
Current Neuropharmacology The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Diabetic Nephropathy
Current Drug Targets Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration
Current Neurovascular Research Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness
Current Diabetes Reviews Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review
Current Neuropharmacology Neuronal High-Affinity Sodium-Dependent Glutamate Transporters (EAATs): Targets for the Development of Novel Therapeutics Against Neurodegenerative Diseases
Current Pharmaceutical Design Role of Free Radicals and Antioxidant Signaling in Skeletal Muscle Health and Pathology
Infectious Disorders - Drug Targets Genes of Human Longevity: An Endless Quest?
Current Vascular Pharmacology The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy
Current Drug Targets Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Minimally-Invasive and Non-Invasive Continuous Glucose Monitoring Systems: Indications, Advantages, Limitations and Clinical Aspects
Current Diabetes Reviews Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Type 2 Diabetes Mellitus in Saudi Arabia: Major Challenges and Possible Solutions
Current Diabetes Reviews p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Oxidative RNA Damage and Neurodegeneration
Current Medicinal Chemistry Targeting ENaC as a Molecular Suspect in Cystic Fibrosis
Current Drug Targets